Ducommun (DCO) is back in focus after being reclassified across several Russell indexes, including multiple growth benchmarks, while its stock recently moved higher alongside stronger defense and commercial aerospace trends.
See our latest analysis for Ducommun.
For context, Ducommun's recent index reclassification comes alongside strong momentum, with a 30 day share price return of 28.01% and a year to date share price return of 96.54%. The 1 year total shareholder return of 129.63% and 3 year total shareholder return of more than 3x indicate investors have been rewarded over both shorter and longer periods.
If you are looking to see what else is moving on the back of defense and aerospace spending, it could be a good moment to check out 35 power grid technology and infrastructure stocks
With Ducommun now trading near recent highs after its index reshuffle and the continuation of aerospace and defense momentum, the key question is whether the stock still trades at a discount or if the market is already pricing in future growth.
Most Popular Narrative: 16% Overvalued
On the latest numbers, Ducommun's most followed valuation narrative points to a fair value of $164 against a last close of $190.25, putting current pricing above that central estimate while still embedding meaningful long term growth assumptions.
Ongoing mix shift toward higher margin engineered products and aftermarket (maintained at 23% of revenues, moving toward 25%+), together with value driven pricing and restructuring actions, is increasing gross margins (recorded at 26.6% in Q2), which supports sustained improvements in net margins and earnings.
Want to see what kind of revenue climb and margin reset would need to stick to justify that fair value and beyond? The narrative leans on a step change in profitability, a re rated earnings multiple and a tighter link between cash flow and reported earnings. Curious which assumptions carry the most weight in that $164 figure and how sensitive it is to even small changes in execution?
Result: Fair Value of $164 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ducommun's narrative could quickly be tested if commercial aerospace destocking lingers longer than expected, or if execution issues around facility consolidations hit margins.
Find out about the key risks to this Ducommun narrative.
Another View: Ducommun Through A Sales Multiple Lens
The overvalued fair value of $164 from the most popular Ducommun narrative sits alongside a very different signal from its P/S ratio. At 3.4x sales, the stock is cheaper than both the US Aerospace & Defense industry average of 5.6x and a 7.5x peer average, yet trades above an estimated fair ratio of 1.5x, which suggests the market could still re rate the multiple lower. Which signal do you trust more when the quality story and the entry price are pointing in different directions?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Ducommun's mixed signals on valuation and sentiment in mind, take a moment to review the underlying data yourself and then weigh the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Ducommun?
Do not stop with Ducommun. Use this moment to broaden your watchlist and uncover other stocks that might fit your goals before the next move happens.
- Target potential mispricings by scanning for companies that combine quality metrics with attractive valuations through the screener containing 19 high quality undiscovered gems.
- Anchor your portfolio with companies that have resilient fundamentals by running the solid balance sheet and fundamentals stocks screener (47 results).
- Cut through noise and focus on companies that score well on both quality and value using the 41 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com